Drug Profile

INV 9956

Alternative Names: INV-9956

Latest Information Update: 30 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shenzhen Ionova Life Sciences Co., Ltd.
Class Antineoplastics
Mechanism of Action Cholesterol side chain cleavage enzyme inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Prostate cancer

Most Recent Events

24 Sep 2024 Shenzhen Ionova Life Sciences Co., Ltd plans a phase I trial for Prostate cancer (Late-stage disease, Metastatic disease, Combination therapy, Hormone refractory) in USA (NCT06609005)
05 Apr 2024 INV 9956 is available for licensing as of 05 Apr 2024. https://www.ionovabio.com/en/solution
05 Apr 2024 Preclinical trials in Prostate cancer in China (PO), before April 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com